- Home
- Publications
- Publication Search
- Publication Details
Title
Pembrolizumab for the treatment of diffuse large B-cell lymphoma
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 19, Issue 11, Pages 1119-1126
Publisher
Informa UK Limited
Online
2019-08-28
DOI
10.1080/14712598.2019.1659777
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
- (2019) Stephen M. Ansell et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype
- (2019) James Godfrey et al. BLOOD
- Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
- (2018) W Jurczak et al. ANNALS OF ONCOLOGY
- How I manage patients with relapsed/refractory diffuse large B cell lymphoma
- (2018) Christian Gisselbrecht et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
- (2018) Jun Zhang et al. Frontiers in Oncology
- PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
- (2017) Tomas Jelinek et al. IMMUNOLOGY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
- (2016) A. Viardot et al. BLOOD
- Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
- (2016) David Belada et al. Future Oncology
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
- (2016) Keisuke Kataoka et al. NATURE
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- Targetable genetic features of primary testicular and primary central nervous system lymphomas
- (2015) B. Chapuy et al. BLOOD
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
- (2015) Dohee Kwon et al. HISTOPATHOLOGY
- Recurrent genomic rearrangements in primary testicular lymphoma
- (2015) David DW Twa et al. JOURNAL OF PATHOLOGY
- Structural genomic alterations in primary mediastinal large B-cell lymphoma
- (2015) David D. W. Twa et al. LEUKEMIA & LYMPHOMA
- Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
- (2014) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma
- (2014) Matthew J. Ahearne et al. VIRCHOWS ARCHIV
- Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
- (2013) N. Mounier et al. HAEMATOLOGICA
- Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry
- (2011) Roel J.W. van Kampen et al. JOURNAL OF CLINICAL ONCOLOGY
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR
- (2009) Hillard M. Lazarus et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma
- (2008) Tara Seshadri et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma
- (2008) John Kuruvilla et al. LEUKEMIA & LYMPHOMA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search